An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered Following Various Caloric Intakes As Compared To The Immediate Release Formulation.

Trial Profile

An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered Following Various Caloric Intakes As Compared To The Immediate Release Formulation.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Epilepsy; Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Postherpetic neuralgia; Postoperative pain; Restless legs syndrome
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Jul 2010 Actual number of patients added to 24 as reported by ClinicalTrials.gov.
    • 06 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top